EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--May 3, 2006--Savient Pharmaceuticals, Inc. (NASDAQ:SVNT - News) a specialty pharmaceutical company focused on developing, manufacturing and marketing novel therapeutic products for unmet medical needs, announced today that the Company has received written notification from the U.S. Food and Drug Administration (FDA) that the Agency has approved a Special Protocol Assessment (SPA) for the two replicate Phase 3 clinical trials for its lead drug, Puricase® (PEG-uricase). As previously announced the Company held its Phase 3 clinical investigators meeting at the end of March and plans to begin patient dosing in May.
